The company had successful launches of its Visium instrument in late 2022 and its new Xenium platform in early 2023. In addition, 10x Genomics defended its intellectual property in 2023 ...

CEO Serge Saxonov, PhD, says provider of single cell, spatial, and in situ instruments expects to see benefits from sales ...

10x Genomics (NASDAQ:TXG) has built a reputation as a trailblazer in recent years, with cutting-edge single-cell and spatial technologies. The firm's Chromium, Visium and Xenium platforms have ...

X Genomics Inc (TXG) stock saw a decline, ending the day at $14.84 which represents a decrease of $-0.01 or -0.07% from the prior close of $14.85. The stock opened at $14.99 and touched a low of ...

The Xenium platform includes a versatile and easy-to-use instrument, sensitive and specific chemistry, a diverse menu of customizable panels, and powerful visualization software. 10x Genomics delivers ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

X Genomics Inc (TXG) stock saw a decline, ending the day at $14.9 which represents a decrease of $-1.41 or -8.65% from the prior close of $16.31. The stock opened at $16.1 and touched a low of $14.19 ...

Weiss Ratings reaffirmed their sell (e+) rating on shares of 10x Genomics (NASDAQ:TXG – Free Report) in a report released on Saturday,Weiss Ratings reports. TXG has been the subject of several other ...

In a report released today, Michael Ryskin from Bank of America Securities maintained a Hold rating on 10x Genomics (TXG – Research Report).

10X Genomics specializes in developing and manufacturing genomics analysis technologies. The company's product portfolio includes the Chromium and Spatial platforms, as well as the Xenium line of ...